UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 17, 2004
--------------------------------
INTEGRATED BIOPHARMA, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware 000-28876 22-2407475
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
225 Long Ave., Hillside, New Jersey 07205
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (973) 926-0816
NOT APPLICABLE
(Former Name or Former Address, if Changed Since Last Report)
ITEM 7. Financial Statements and Exhibits.
(c) Exhibits
Exhibit Number Description
99.1 Press Release of Integrated BioPharma, Inc. dated May 17, 2004
reporting results for the quarter ended March 31, 2004.
ITEM 9. Regulation FD Disclosure.
In accordance with SEC Release No. 33-8216, the following information,
required to be furnished under "Item 12. Results of Operations and Financial
Condition," is furnished under "Item 9. Regulation FD Disclosure".
On May 17, 2004 the Company issued a press release reporting results
for the quarter ended March 31, 2004, the text of which is attached hereto as
Exhibit 99.1 and incorporated herein in its entirety by reference.
The statements in this Current Report on Form 8-K, including the
exhibits, contain forward-looking statements and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that forward-looking statements involve risk and
uncertainties which may affect the Registrant's business prospects, including
economic, competitive, governmental, technological and other factors discussed
in filings with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
INTEGRATED BIOPHARMA, INC.
May 17, 2004 By: /s/Eric Friedman
Name: Eric Friedman
Title: Vice President
EXHIBIT INDEX
Exhibit Number Description
99.1 Press Release of Integrated BioPharma, Inc. dated May 17,
2004 reporting results for the quarter ended March 31, 2004.